BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31309879)

  • 1. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role.
    Schizas D; Mastoraki A; Naar L; Tsilimigras DI; Katsaros I; Fragkiadaki V; Karachaliou GS; Arkadopoulos N; Liakakos T; Moris D
    Curr Med Chem; 2020; 27(36):6099-6111. PubMed ID: 31309879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment.
    Schizas D; Mastoraki A; Naar L; Spartalis E; Tsilimigras DI; Karachaliou GS; Bagias G; Moris D
    World J Gastroenterol; 2018 Nov; 24(41):4635-4642. PubMed ID: 30416311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
    Mastoraki A; Schizas D; Vlachou P; Melissaridou NM; Charalampakis N; Fioretzaki R; Kole C; Savvidou O; Vassiliu P; Pikoulis E
    Mol Diagn Ther; 2020 Oct; 24(5):557-569. PubMed ID: 32696211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of histone deacetylases (HDACs) in human cancer.
    Ropero S; Esteller M
    Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of histone deacetylases.
    Huang Y; Shaw PG; Davidson NE
    Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of histone deacetylases inhibitors in glioblastoma.
    Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
    J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
    Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
    Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histone modification and its application in therapy for hematologic malignancies -- review].
    Fang MH; Ji XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):816-20. PubMed ID: 19549415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone acetylation and the cell-cycle in cancer.
    Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG
    Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
    Hadnagy A; Beaulieu R; Balicki D
    Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of HDACs in normal and malignant hematopoiesis.
    Wang P; Wang Z; Liu J
    Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.